List of Tables
Table 1. Global Intermediate CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Antibiotic Intermediates
Table 3. Key Players of Antipyretic and Analgesic Intermediate
Table 4. Key Players of Cardiovascular System Drug Intermediates
Table 5. Key Players of Anticancer Drug Intermediates
Table 6. Global Intermediate CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Intermediate CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Intermediate CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Intermediate CDMO Market Share by Region (2020-2025)
Table 10. Global Intermediate CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Intermediate CDMO Market Share by Region (2026-2031)
Table 12. Intermediate CDMO Market Trends
Table 13. Intermediate CDMO Market Drivers
Table 14. Intermediate CDMO Market Challenges
Table 15. Intermediate CDMO Market Restraints
Table 16. Global Intermediate CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Intermediate CDMO Market Share by Players (2020-2025)
Table 18. Global Top Intermediate CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Intermediate CDMO as of 2024)
Table 19. Ranking of Global Top Intermediate CDMO Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Intermediate CDMO Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Intermediate CDMO, Headquarters and Area Served
Table 22. Global Key Players of Intermediate CDMO, Product and Application
Table 23. Global Key Players of Intermediate CDMO, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Intermediate CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Intermediate CDMO Revenue Market Share by Type (2020-2025)
Table 27. Global Intermediate CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Intermediate CDMO Revenue Market Share by Type (2026-2031)
Table 29. Global Intermediate CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Intermediate CDMO Revenue Market Share by Application (2020-2025)
Table 31. Global Intermediate CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Intermediate CDMO Revenue Market Share by Application (2026-2031)
Table 33. North America Intermediate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Intermediate CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Intermediate CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Intermediate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Intermediate CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Intermediate CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Intermediate CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Intermediate CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Intermediate CDMO Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Intermediate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Intermediate CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Intermediate CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Intermediate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Intermediate CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Intermediate CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 48. Pharmira Company Details
Table 49. Pharmira Business Overview
Table 50. Pharmira Intermediate CDMO Product
Table 51. Pharmira Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 52. Pharmira Recent Development
Table 53. AGC Inc Company Details
Table 54. AGC Inc Business Overview
Table 55. AGC Inc Intermediate CDMO Product
Table 56. AGC Inc Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 57. AGC Inc Recent Development
Table 58. Blue Jet Healthcare Company Details
Table 59. Blue Jet Healthcare Business Overview
Table 60. Blue Jet Healthcare Intermediate CDMO Product
Table 61. Blue Jet Healthcare Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 62. Blue Jet Healthcare Recent Development
Table 63. Drug Discovery Alliances Company Details
Table 64. Drug Discovery Alliances Business Overview
Table 65. Drug Discovery Alliances Intermediate CDMO Product
Table 66. Drug Discovery Alliances Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 67. Drug Discovery Alliances Recent Development
Table 68. KriSan Biotech Company Details
Table 69. KriSan Biotech Business Overview
Table 70. KriSan Biotech Intermediate CDMO Product
Table 71. KriSan Biotech Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 72. KriSan Biotech Recent Development
Table 73. Saurav Chemicals Company Details
Table 74. Saurav Chemicals Business Overview
Table 75. Saurav Chemicals Intermediate CDMO Product
Table 76. Saurav Chemicals Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 77. Saurav Chemicals Recent Development
Table 78. Olon SpA Company Details
Table 79. Olon SpA Business Overview
Table 80. Olon SpA Intermediate CDMO Product
Table 81. Olon SpA Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 82. Olon SpA Recent Development
Table 83. AGC Biologics Company Details
Table 84. AGC Biologics Business Overview
Table 85. AGC Biologics Intermediate CDMO Product
Table 86. AGC Biologics Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 87. AGC Biologics Recent Development
Table 88. Fermion Company Details
Table 89. Fermion Business Overview
Table 90. Fermion Intermediate CDMO Product
Table 91. Fermion Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 92. Fermion Recent Development
Table 93. Pfizer CentreOne Company Details
Table 94. Pfizer CentreOne Business Overview
Table 95. Pfizer CentreOne Intermediate CDMO Product
Table 96. Pfizer CentreOne Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 97. Pfizer CentreOne Recent Development
Table 98. Aspen Holdings Company Details
Table 99. Aspen Holdings Business Overview
Table 100. Aspen Holdings Intermediate CDMO Product
Table 101. Aspen Holdings Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 102. Aspen Holdings Recent Development
Table 103. Educell Company Details
Table 104. Educell Business Overview
Table 105. Educell Intermediate CDMO Product
Table 106. Educell Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 107. Educell Recent Development
Table 108. Hovione Company Details
Table 109. Hovione Business Overview
Table 110. Hovione Intermediate CDMO Product
Table 111. Hovione Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 112. Hovione Recent Development
Table 113. Porton Pharma Solutions Company Details
Table 114. Porton Pharma Solutions Business Overview
Table 115. Porton Pharma Solutions Intermediate CDMO Product
Table 116. Porton Pharma Solutions Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 117. Porton Pharma Solutions Recent Development
Table 118. Sinopep Company Details
Table 119. Sinopep Business Overview
Table 120. Sinopep Intermediate CDMO Product
Table 121. Sinopep Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 122. Sinopep Recent Development
Table 123. Chongqing Huapont Pharmaceutical Company Details
Table 124. Chongqing Huapont Pharmaceutical Business Overview
Table 125. Chongqing Huapont Pharmaceutical Intermediate CDMO Product
Table 126. Chongqing Huapont Pharmaceutical Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 127. Chongqing Huapont Pharmaceutical Recent Development
Table 128. Langhua Pharmaceutical Company Details
Table 129. Langhua Pharmaceutical Business Overview
Table 130. Langhua Pharmaceutical Intermediate CDMO Product
Table 131. Langhua Pharmaceutical Revenue in Intermediate CDMO Business (2020-2025) & (US$ Million)
Table 132. Langhua Pharmaceutical Recent Development
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Intermediate CDMO Picture
Figure 2. Global Intermediate CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Intermediate CDMO Market Share by Type: 2024 VS 2031
Figure 4. Antibiotic Intermediates Features
Figure 5. Antipyretic and Analgesic Intermediate Features
Figure 6. Cardiovascular System Drug Intermediates Features
Figure 7. Anticancer Drug Intermediates Features
Figure 8. Global Intermediate CDMO Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Intermediate CDMO Market Share by Application: 2024 VS 2031
Figure 10. Pharmaceutical Company Case Studies
Figure 11. Biotechnology Company Case Studies
Figure 12. Generic Company Case Studies
Figure 13. Others Case Studies
Figure 14. Intermediate CDMO Report Years Considered
Figure 15. Global Intermediate CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Intermediate CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Intermediate CDMO Market Share by Region: 2024 VS 2031
Figure 18. Global Intermediate CDMO Market Share by Players in 2024
Figure 19. Global Top Intermediate CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Intermediate CDMO as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Intermediate CDMO Revenue in 2024
Figure 21. North America Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Intermediate CDMO Market Share by Country (2020-2031)
Figure 23. United States Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Intermediate CDMO Market Share by Country (2020-2031)
Figure 27. Germany Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Intermediate CDMO Market Share by Region (2020-2031)
Figure 35. China Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Intermediate CDMO Market Share by Country (2020-2031)
Figure 43. Mexico Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Intermediate CDMO Market Share by Country (2020-2031)
Figure 47. Turkey Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Intermediate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Pharmira Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 51. AGC Inc Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 52. Blue Jet Healthcare Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 53. Drug Discovery Alliances Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 54. KriSan Biotech Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 55. Saurav Chemicals Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 56. Olon SpA Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 57. AGC Biologics Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 58. Fermion Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 59. Pfizer CentreOne Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 60. Aspen Holdings Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 61. Educell Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 62. Hovione Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 63. Porton Pharma Solutions Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 64. Sinopep Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 65. Chongqing Huapont Pharmaceutical Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 66. Langhua Pharmaceutical Revenue Growth Rate in Intermediate CDMO Business (2020-2025)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed